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Abstract
Background: Deleted in Malignant Brain Tumors 1 (DMBT1) is a secreted scavenger receptor cysteine-
rich protein that binds various bacteria and is thought to participate in innate pulmonary host defense. We
hypothesized that pulmonary DMBT1 could contribute to respiratory distress syndrome in neonates by
modulating surfactant function.
Methods: DMBT1 expression was studied by immunohistochemistry and mRNA in situ hybridization in
post-mortem lungs of preterm and full-term neonates with pulmonary hyaline membranes. The effect of
human recombinant DMBT1 on the function of bovine and porcine surfactant was measured by a capillary
surfactometer. DMBT1-levels in tracheal aspirates of ventilated preterm and term infants were
determined by ELISA.
Results: Pulmonary DMBT1 was localized in hyaline membranes during respiratory distress syndrome. In
vitro addition of human recombinant DMBT1 to the surfactants increased surface tension in a dose-
dependent manner. The DMBT1-mediated effect was reverted by the addition of calcium depending on
the surfactant preparation.
Conclusion: Our data showed pulmonary DMBT1 expression in hyaline membranes during respiratory
distress syndrome and demonstrated that DMBT1 increases lung surface tension in vitro. This raises the
possibility that DMBT1 could antagonize surfactant supplementation in respiratory distress syndrome and
could represent a candidate target molecule for therapeutic intervention in neonatal lung disease.
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Respiratory distress syndrome (RDS) in neonates due to
surfactant deficiency has been shown to be associated
with a strong immune response such as activation of com-
plement [1] and neutrophils [2]. Further, ventilation of
preterm infants with RDS results in an increase in macro-
phages and an influx of granulocytes into airspaces [3].
These immune responses may accelerate the damage of
surfactant by increased endothelial permeability and con-
tribute to the formation of hyaline membranes and the
development of chronic lung disease [1,3].
The response of premature infants with primary surfactant
deficiency to intratracheally administered exogenous sur-
factant preparations varies widely. Proposed reasons for a
poor response include deficiencies and genetic variants of
surfactant protein-coding genes [4], extreme lung imma-
turity, delayed surfactant administration [5], mechanical
ventilation [6], variations of surfactant proteins and sur-
face-active lipids in various surfactant preparations [7],
and surfactant inactivation due to increased concentra-
tions of cytokines and other inflammatory components
[1].
Surfactant influences pulmonary immunologic reactions:
The surfactant proteins SP-A and SP-D regulate host
immune defence and modulate inflammatory responses
[8-10]. The complex of lipids and proteins in pulmonary
surfactant enhances pathogen clearance and regulates
adaptive and innate immune-cell functions [11]. Sur-
factant may decrease immunologic functions as leukocyte
activation [12]. On the other hand, intratracheally admin-
istered surfactants may also induce the release of tumor
necrosis factor, IL-6 and IL-8 in animal models [13,14].
DMBT1 (Deleted in Malignant Brain Tumors 1), also known
as glycoprotein-340 (gp-340) or salivary agglutinin
(SAG), is a secreted scavenger receptor cysteine-rich
(SRCR) protein mainly expressed by mucosal epithelia
and glands, in particular within the human respiratory
tract [15]. In the adult respiratory tract, alveolar type II
cells, epithelial cells and associated glands were found to
express DMBT1 [16,17]. While the steady-state DMBT1
levels appear to be low in the adult lung, immunohisto-
chemical studies demonstrated an up-regulation upon
respiratory inflammation [17]. The percentage of DMBT1-
positive type II pneumocytes increases with increasing
severity of inflammation.
DMBT1 secreted into the oral cavity and respiratory tract
is thought to play a role in innate immune defense. The
protein binds and aggregates a broad range of pathogenic
bacteria as well as viruses [18-21], stimulates chemokine-
sis of alveolar macrophages and interacts with other com-
ponents of the innate immune system (e.g. surfactant
protein-D and -A) as well as secretory IgA, which plays a
crucial role in adaptive mucosal immunity [16,22-25].
We hypothesized that DMBT1 could potentially be linked
to the differential response to surfactant supplementa-
tion. Therefore, we studied post-mortem lung sections of
neonates with respiratory distress syndrome, the effects of
DMBT1 on surfactant preparations used in supplementa-
tion therapies as well as the DMBT1-level in tracheal aspi-
rates of ventilated preterm and term infants.
Methods
Immunohistochemistry
We studied the expression of DMBT1 in lungs of seven
newborn infants (preterm infants n = 5; full-term infants
n = 2; table 1), born in 2001 – 2004, with post-mortem
examination at the Institute of Pathology, University of
Heidelberg, Germany.
The analyses were approved by the responsible ethics
committee. All infants showed intrapulmonary hyaline
membranes because of respiratory distress syndrome in
prematurity (n = 3), idiopathic respiratory distress syn-
drome (n = 1) and shock (n = 4; table 1). The total situa-
tion of the infants without surfactant application was so
Table 1: Data of patients with post-mortem examination
Preterm infants GA at birth GA at death Prenatal 
corticosteroids
Postnatal 
corticosteroids
Surfactant RDS/IRDS Acute shock lung 
(ASL)
1 23 23 no yes yes RDS ASL
2 27 28 yes yes yes RDS no
3 28 30 yes no no no ASL
4 28 28 yes no yes RDS no
5 35 35 no yes no IRDS no
Term infants
6 38 44 no no no no ASL
7 40 46 no no no no ASLPage 2 of 10
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changed the hopeless situation. Elevated infection param-
eters were diagnosed in four infants with acute bronchop-
neumonia, necrotizing enterocolitis with Klebsiella
pneumonia sepsis, urosepsis and multiple organ failure
after operation of cardiac vitium.
An automated Ventana Discovery stainer (Ventana Medi-
cal Systems, Tucson, USA) and a RedMap staining kit were
used for immunohistochemistry with the polyclonal rab-
bit antiserum anti-DMBT1p84 raised against human
recombinant DMBT1 (hrDMBT1). The sections were incu-
bated with anti-DMBT1p84 antibody, diluted 1:100 in
Discovery Ab Diluent, for 40 minutes followed by incuba-
tion for 30 minutes with mouse anti-rabbit IgG-AP (Santa
Cruz Biotechnology, final dilution of 1:500). Immunohis-
tochemistry with the monoclonal antibody anti-
DMBT1h12 was carried out under the conditions
described earlier [26]. As negative control sections were
stained with equal amounts of either normal rabbit serum
or anti-DMBT1p84 preincubated with hrDMBT1, or with
normal mouse IgG (Santa Cruz Biotechnology). Preincu-
bation of the polyclonal antiserum was performed by a
1:100 dilution of the anti-DMBT1p84 with a 100 µg/ml
hrDMBT1 solution, followed by an incubation step at
37°C for 30 minutes prior use for the staining procedure.
The control sections were negative for DMBT1 staining
(data not shown).
mRNA in situ hybridization
For in situ hybridization we used also formalin-fixed, par-
affin-embedded tissue sections (3–4 µm). First, the sec-
tions were deparaffinized and rehydrated by xylene and a
series of graded ethanols. Incubation with paraformalde-
hyde (PFA) for 10 minutes at 4°C was followed by block-
ing the endogenous peroxidase with 1% H2O2 in PBS for
20 minutes. Then the tissue sections were digested with 10
µg/ml proteinase K for 30 minutes at 37°C. Next, the sec-
tions were treated with 0.1 M triethanolamine (pH 8.0)
for 20 minutes and further dehydrated by a series of
graded ethanols. After prehybridization we incubated the
slides with single stranded probe against the coding
sequence for SRCR 6 of DMBT1 (antisense) at 47°C over
night. The sense probe as negative control was used in par-
allel with the antisense probe on consecutive tissue sec-
tions within each experiment. The slides were treated with
2 × SSC at 47°C for 30 minutes and incubated with 50%
formamide, 0.5 × SSC for 1 hour, with 50% formamide,
0.1 × SSC for 30 minutes at 47°C and finally with 0.2 ×
SSC for 10 minutes at room temperature.
The subsequent steps with TSA-amplification are part of
the TSA™ Biotin System Kit (NEN™ Life Science Products).
Blocking with TNB buffer was done for 30 minutes at
room temperature. Incubation with the antibody anti-
DIG-HRP, concentrated 1:100 in TNB buffer, took place
for 30 minutes in a humidified chamber at room temper-
ature. Peroxidase activity was detected by 3-amino-9-
ethylcarbazole as a substrate. Finally sections were coun-
terstained with Mayer's Hematoxylin and mounted in
crystal mount (Biomeda) for microscopic examination.
Production and purification of human recombinant 
DMBT1 (hrDMBT1)
The production and purification of hrDMBT1 was essen-
tially performed as described elsewhere [27]. Briefly, the
hrDMBT1 producer cell line T3 was induced with 10 µg/
ml tetracycline for 48 h. Afterwards, the hrDMBT1-con-
taining supernatant was collected and the protein was iso-
lated by mixing the supernatant with a suspension of S.
gordonii. Bound hrDMBT1 was eluted by using PBS buffer
containing 10 mM EDTA. The eluted protein was concen-
trated and applied to a size-exclusion chromatography
column. The purity of hrDMBT1-preparations was con-
firmed by SDS-PAGE and silver staining. The concentra-
tion of purified hrDMBT1 was determined with the Micro
BCA Protein Assay Reagent Kit (Pierce, Rockford, USA).
Analysis of the effect of DMBT1 on surface tension of 
surfactant preparations
We used two different exogenous surfactant preparations
for the studies: Curosurf® (extract of minced porcine lung;
Nycomed Pharma GmbH, Unterschleißheim, Germany)
and Alveofact® (surfactant extracted from bovine lung lav-
age; Boehringer Ingelheim Pharma GmbH, Ingelheim,
Germany). Both surfactants are lipid extracts and contain
about 1% proteins (surfactant protein-B and surfactant
protein-C).
The surface tension of the surfactant preparations was
measured by a capillary surfactometer (Calmia Medical,
Toronto, ON, Canada, [28]) as described previously [29].
Briefly, glass capillaries (0.255 mm internal diameter at its
narrowest part) were filled with 0.5 µl of a surfactant sus-
pension and subsequently we assessed the capability to
keep the capillary open over a time period of 120 seconds.
Distilled water (0%  of the time open) and a purified
bovine surfactant (96.7% of the time open)  at 37°C
served as controls [29]. The device simulates the morphol-
ogy and functions of terminal conducting airways [28,29].
The "% of the time open" is used as an index of surface
activity which is inversely related to the surface tension of
surfactant.
Different concentrations (final concentrations: 0 – 330
µg/ml) of purified human DMBT1 recombinantly
expressed in mammalian cells were added to the sur-
factant preparations and surface activity was measured in
the presence or absence of calcium chloride (0 – 5 mM).
Surface activity of each sample was measured at least threePage 3 of 10
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ity of hrDMBT1 on its tertiary structure we inactivated
hrDMBT1 (final concentration: 200 µg/ml) by heating at
95°C for 30 minutes. Because hrDMBT1 was dissolved in
PBS, we used surfactant preparations with equivalent vol-
umes of PBS added as controls. To analyze the effect of
hrDMBT1 concentration on surface tension in different
surfactant preparations and the effects of calcium we used
2-way- and 1-way-ANOVAs. P values smaller than 0.05
were regarded as statistically significant.
Tracheal aspirates
DMBT1 concentration was determined in a total of 121
tracheal aspirates of 57 ventilated preterm and term
infants treated at the Perinatal Center of the University of
Heidelberg in 2001 – 2004. The study was approved by
the Ethics Committee. 52 of the 57 infants were preterm
(mean birth weight: 1262 g, range 370 – 3915 g, mean
gestational age at birth: 28 weeks, range 23 – 36 weeks).
43 of the 52 preterm infants (83%) showed RDS (mild
RDS: n = 19, severe RDS: n = 24). Only 1 of the 5 term
infants (mean birth weight: 3298 g, range 2420 – 3860 g,
mean gestational age at birth: 39 weeks, range 37 – 40
weeks) had hyaline membranes. The tracheal aspirates
were collected by instillation of sterile saline 0.9%
through the endotracheal tube (<1000 g body weight
(gbw) 0.5 ml; >1000 gbw 1.0 ml) and suctioned once or
twice after three breaths of manual or mechanical ventila-
tion. Subsequently, samples were additionally diluted to
reach a total dilution of approximately 1:10 of the epithe-
lial lining fluid (ELF). Samples were stored at -20°C until
used for ELISA measurements.
Determination of the DMBT1 concentration in tracheal 
aspirates of neonates and in surfactant preparations by 
ELISA (enzyme-linked immunosorbent assay)
Microtiter plates (Microlon, F-Shape, Greiner Bio-One,
Frickenhausen, Germany) were coated with different dilu-
tions of tracheal aspirates and with the surfactant prepara-
tions (Curosurf® and Alveofact®) in coating buffer
(carbonate buffer, pH 9.6) and incubated overnight at
4°C. Subsequently, the plates were washed with TBS-T
and incubated with the DMBT1-specific monoclonal
mouse antibody Hyb213-06 (Antibodyshop, Gentofte,
Denmark, [16]) diluted 1:5000 for 1 h at room tempera-
ture. After three washes with TBS-T, the wells were incu-
bated with a horseradish peroxidase-conjugated anti-
mouse IgG (1:5000) for 1 h at room temperature. After
washing, the bound enzyme was detected by adding TMB-
substrate solution (125 µg/ml 3,3',5,5'-Tetramethyl-ben-
zidine; 125 µg/ml in 0.1 M citrate buffer pH 4.5 with
0.05% (v/v) H2O2). The reaction was stopped by addition
of 2 M HCl after incubation for 20 minutes in the dark.
The intensity of the dye reaction was measured at 450 nm
in an ELISA reader (EL800; Bio-Tec Instruments Inc.).
Human recombinant DMBT1 was used as standard.
Results
DMBT1 expression in respiratory epithelia, glands and 
hyaline membranes of preterm and term infants
The expression of DMBT1 was analyzed in postmortem
lung sections of preterm and term infants by immunohis-
tochemistry. DMBT1 expression was found in alveolar
epithelial and glandular cells as well as in hyaline mem-
branes of preterm infants with respiratory distress syn-
drome (RDS) and acute shock lung, and in hyaline
membranes of term infants with acute shock lungs. Paral-
lel treatments of consecutive lung sections with a DMBT1-
specific monoclonal antibody (anti-DMBT1h12) and a
DMBT1-specific polyclonal antiserum (anti-DMBT1p84)
revealed similar staining patterns of respiratory epithelia
cells and glands. The monoclonal antibody anti-
DMBT1h12 gave stronger staining signals in epithelial
cells, whereas the usage of anti-DMBT1p84 resulted in
stronger staining signals of respiratory glands and mucus.
In situ hybridizations confirmed the observed expression
patterns. DMBT1 mainly localize on the cell surface, i.e.
below/above the surfactant layer. Figure 1, panels A, B and
C, show lung sections of two preterm infants (no. 1; no. 4
of table 1) who died from severe hyaline membrane dis-
ease without infection. DMBT1 expression was found in
the hyaline membranes illustrated in the lung section of a
preterm infant with primary surfactant deficiency and
shock (Fig. 1A) as well as in the lung sections of a preterm
infant with RDS caused by primary surfactant deficiency
(Fig. 1B, 1C). Figure 1D presents a lung section of a pre-
term infant born at 27 weeks of gestation (no. 2 of table
1). The infant developed severe bronchopneumonia, sur-
factant deficiency, and formation of hyaline membranes.
The infant received eleven doses of natural bovine sur-
factant preparation (Alveofact®), but died after 8 days due
to bronchopneumonia and pulmonary interstitial
emphysema with concomitant respiratory failure. The
hyaline membranes stained strongly for DMBT1, which
was confirmed by mRNA in situ hybridization revealing
corresponding signals in the underlying cells (Fig. 1D – F).
In Figure 2 the time course of mechanical ventilation of
this preterm infant (no. 2 of table 1) with high DMBT1
levels is presented. High mean airway pressures and differ-
ent forms of mechanical ventilation (synchronized inter-
mittent mechanical ventilation, high-frequency
ventilation) had to be used to reach sufficient oxygenation
(Fig. 2). This was accompanied by multiple pneumotho-
races and by interstitial emphysema. Multiple applica-
tions of surfactant and inhalation of nitric oxide were not
able to change this fatal situation. At day 8 the preterm
infant died as a consequence of insufficient oxygenation.Page 4 of 10
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DMBT1 expression in hyaline membranesFigure 1
DMBT1 expression in hyaline membranes. Analysis of DMBT1 expression in post-mortem lung sections of preterm 
infants. Binding of anti-DMBT1p84 displayed as red staining (arrows). (A) Lung section of a preterm infant born at 23 weeks of 
gestation without infection, who died at the same day because of primary surfactant deficiency and shock after resuscitation, 
illustrating respiratory DMBT1 expression in hyaline membranes. (B) Lung section of a neonate with primary surfactant defi-
ciency born at 28 weeks and dying on day 2 without infection, which demonstrates DMBT1 expression in hyaline membranes. 
(C) Higher lung magnification of (B). (D) Lung tissue of a preterm infant with pneumonia born at 27 weeks who died at a gesta-
tional age of 28 weeks. (E, F) mRNA in situ hybridization of lung section (D) confirmed the results obtained from immunohisto-
chemical analyses.
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in vitro
We next aimed at exploring the effect of DMBT1 on two
different surfactant preparations which are used in supple-
mentation therapies for preterm infants. Upon ELISA
measurements, there were neither detectable levels of
DMBT1-homologues in bovine Alveofact® nor porcine
Curosurf®. Surfactometer measurements demonstrated
that the addition of hrDMBT1 to the surfactant prepara-
tions decreased the surface activity (i.e. increased the sur-
face tension) of both Curosurf® and Alveofact® in a dose-
dependent manner (Fig. 3). However, the hrDMBT1 con-
centration needed to reduce the surface activity by 50%
was about 2.5 fold higher for Curosurf® (110 µg/ml
hrDMBT1) than for Alveofact® (45 µg/ml hrDMBT1) indi-
cating that Alveofact® is less resistant to the presence of
DMBT1 (Fig. 3A). Analysis by 2-way-ANOVA showed a
significant influence on surface tension depending on the
surfactant preparation (P = 0.0243) and on the hrDMBT1
concentration (P < 0.0001) as well as an interaction
between surfactant preparation and hrDMBT1 concentra-
tion (P = 0.0363), which confirmed that the concentra-
tion influence is different in the two surfactant
preparations. Therefore, each surfactant preparation was
investigated by a 1-way-ANOVA. For Alveofact® and Curo-
surf®, a highly significant influence of hrDMBT1 on the
surface tension could be shown (P < 0.0001 or P = 0.0001,
respectively).
The decrease of surface activity induced by 200 µg/ml
hrDMBT1 was completely abolished by 1 mM CaCl2 for
Curosurf®, whereas 5 mM CaCl2 was necessary to obtain a
comparable effect for Alveofact® (Fig. 3B). Also in this set-
ting the 2-way-ANOVA pointed to an influence of sur-
factant preparation (P = 0.0004), of hrDMBT1
concentration (P < 0.0001) and an interaction relation
Effects of increasing hrDMBT1 (A) and calcium (B) concen-trations on surface activity of surfactant preparationsFigure 3
Effects of increasing hrDMBT1 (A) and calcium (B) 
concentrations on surface activity of surfactant prep-
arations. (A) Surface activity (assessed as openness of a cap-
illary) decreased with increasing human recombinant DMBT1 
concentrations (final concentrations: 0 – 330 µg/ml) in both 
surfactant preparations (final phospholipid concentration 1 
mg/ml). 2-way-ANOVA showed a significant influence on 
surface tension for surfactant preparation (P = 0.0243) and 
for hrDMBT1 concentration (P < 0.0001) as well as an inter-
action between surfactant preparation and hrDMBT1 con-
centration (P = 0.0363). (B) Calcium chloride antagonized 
the decrease of surface activity in the surfactant preparations 
(final phospholipid concentration 1 mg/ml) induced by 
hrDMBT1 (final concentration: 200 µg/ml). Analysis of vari-
ance analysis stated an influence of surfactant preparation (P 
= 0.0004), of hrDMBT concentration (P < 0.0001) and an 
interaction between surfactant preparation and hrDMBT1 
concentration (P = 0.0037). Note that the surface activity of 
Alveofact® decreased at a lower hrDMBT1 concentration 
than that of Curosurf® (A) and that calcium antagonized the 
hrDMBT1 effect at 1 mM, whereas Alveofact® required a cal-
cium concentration >3 mM (B). Data are expressed as mean 
± SEM.
Ventilation therapy in an infant with hyaline membranesFigure 2
Ventilation therapy in an infant with hyaline mem-
branes. Time courses of mechanical ventilation therapy and 
its complications in a preterm infant with bronchopneumonia 
that was born with 27 weeks and died at day eight (panel D-F 
of figure 1). The course of mean airway pressure is displayed 
in mbar. Red squares are mean airway pressure values under 
conventional ventilation (triangular airway pressure wave-
form) and black squares are mean airway pressure values 
under high-frequency ventilation (9 Hz). Black boxes: applica-
tion of bovine surfactant (Alveofact®); empty boxes: diagno-
sis of pneumothorax; orange box: administration of nitrite 
oxygen.Page 6 of 10
(page number not for citation purposes)
Respiratory Research 2007, 8:69 http://respiratory-research.com/content/8/1/69between surfactant preparation and hrDMBT1 concentra-
tion (P = 0.0037). One-way-ANOVA revealed a significant
influence of hrDMBT1 concentration in Alveofact® as well
as in Curosurf® (P = 0.0034 and P < 0.0001, respectively).
These data demonstrate that hrDMBT1 has a differential
effect on the surface tension of different surfactants in
vitro, which can be antagonized by the addition of calcium
chloride.
To assess the dependence of the inhibitory activity of
DMBT1 on its tertiary structure, heat-inactivated
hrDMBT1 (final concentration: 200 µg/ml) was added to
Curosurf® or Alveofact®, both with a final phospholipid
concentration of 1 mg/ml. No inhibitory effect of heat-
treated hrDMBT1 was found on the surface activity of the
used porcine and bovine surfactant preparations (Fig. 4).
DMBT1 levels in tracheal aspirates of preterm and term 
infants
Surfactometer measurements indicate that DMBT1 is able
to increase the surface tension of two different surfactant
preparations, which would have a negative impact on the
treatment of preterm infants. In order so see whether the
DMBT1 concentrations used in the in vitro experiments
match to the concentrations present in vivo, we analyzed
121 tracheal aspirates (TAs) of 57 preterm and term
infants in ELISA (Fig. 5). The 1:10 diluted TAs contained
a mean DMBT1 concentration of 5.2 ± 1.8 µg/ml with a
lowest DMBT1 concentration of 0.2 µg/ml and a highest
of 25 µg/ml, respectively (Fig. 5). In summary 47% of the
analyzed tracheal aspirates showed a DMBT1 concentra-
tion of more than 15 µg/ml.
Discussion
Insufficient surfactant production or inactivation of sur-
factant is a frequent cause for mechanical ventilation and
surfactant application in neonatology. Surfactant defi-
ciency results in alveolar collapse and impaired gas
exchange associated with the requirement of high pres-
sure in mechanical ventilation and with the appearance of
pneumothoraces. We studied the expression of the
secreted scavenger receptor cysteine-rich protein DMBT1
in ventilated preterm and term infants. Our results dem-
onstrate that respiratory epithelial cells and glands of pre-
term and term neonates expressed DMBT1. We found out
that DMBT1 was located in hyaline membranes of pre-
term infants with RDS and acute shock and of term infants
with acute shock lungs. DMBT1 was mainly found on the
surface, i.e. below/above the surfactant layer. DMBT1 is
thought to be a critical factor of innate defence mecha-
nisms, therefore its strong expression in preterm infants is
in agreement with the strong immune response induced
by RDS [1,2].
In neonatology the introduction of surfactant application
was a great success in the treatment of neonates and con-
tributes to survival of very low birth weight infants. Our
investigations revealed that DMBT1 (hrDMBT1) is able to
DMBT1 concentration in 1:10 diluted tracheal aspirates of preterm and term infants without correction for epitheliallining fluid dilutionFigure 5
DMBT1 concentration in 1:10 diluted tracheal aspi-
rates of preterm and term infants without correction 
for epithelial lining fluid dilution. The DMBT1 concen-
tration in 121 tracheal aspirates of 57 ventilated preterm and 
term infants was analyzed by ELISA using the monoclonal 
antibody Hyb213-06. The mean DMBT1 concentration was 
5.2 ± 1.8 µg/ml. Due to our sampling procedure of tracheal 
aspirates and due to an additional dilution after sampling, we 
estimate the volume of epithelial lining fluid in our tracheal 
aspirates to be at least one-tenth of the recovered volume.
In vitro surfactometer measurements of surface activityFigure 4
In vitro surfactometer measurements of surface 
activity. Pure surfactants (final phospholipid concentration 1 
mg/ml) showed high surface activity (100% open). Human 
recombinant DMBT1 (final concentration: 200 µg/ml) 
decreased the surface activity of Alveofact® and Curosurf® 
(final phospholipid concentration 1 mg/ml). Heat-inactivated 
hrDMBT1 had no effect on surface activity.Page 7 of 10
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tions (Curosurf®; Alveofact®) in a dose dependent manner
(Fig. 3). A 50% reduction of surface activity was observed
in Alveofact® by 45 µg/ml hrDMBT1 and in Curosurf® by
110 µg/ml hrDMBT1 indicating that Alveofact® is less
resistant to the presence of DMBT1. The presence of
DMBT1 in epithelial lining fluid of ventilated preterm and
term infants could be confirmed by ELISA measurements
of tracheal aspirates (Fig. 5). DMBT1 concentrations
determined in 1:10 diluted tracheal aspirates by ELISA
were in the range of 0.2 – 25 µg/ml, with a mean concen-
tration of 5 µg/ml DMBT1. A mean DMBT1-concentration
of 130 ± 30 ng/ml has been reported in unconcentrated
bronchoalveolar lavage (BAL) of healthy adults [21].
However, a yield of 0.5 µg DMBT1gp340 per ml BAL from
adult patients with alveolar proteinosis has been
described and indicates much higher DMBT1-levels in the
diseased lung of adults [24]. Both the DMBT1 concentra-
tions measured in BAL fluid [21] and in preterm tracheal
aspirates do not reflect the "real" concentration in the epi-
thelial lining fluid (ELF) because of dilutions during the
lavage and aspirate procedure. The volume of epithelial
lining fluid recovered by lavage in adults has been esti-
mated to be one-hundreth of the recovered lavage volume
[30]. Due to our sampling procedure of tracheal aspirates
and due to an additional dilution after sampling, we esti-
mate the volume of epithelial lining fluid in our tracheal
aspirates to be at least one-tenth of the recovered volume.
This would mean that the local DMBT1 level in epithelial
lining fluid of ventilated preterm infants could indeed
reach a level in which an inactivation of applied surfactant
preparations might occur. Therefore, DMBT1 levels in pre-
term infants might be of importance for the clinical effec-
tiveness of surfactant preparations.
At the present state of the art, it is unclear by which mech-
anisms DMBT1 alters surfactant function. It is conceivable
that DMBT1 may inhibit surfactant absorption to the sur-
face of terminal conducting airways and alveoli. This
mechanism has been proposed for surfactant inactivation
by serum proteins such as albumin and fibrinogen [31].
Addition of albumin or fibrinogen to lung surfactant
changes the characteristic surfactant morphology from a
lamellar rod-like structure with open ends into spherical
structures with loss of their open ends [32].
However, the addition of calcium to the preparations
could partly revert the negative effect of hrDMBT1 on the
surface activity (Fig. 3B). Whereas the addition of 1 mM
CaCl2 overcame the increase of surface tension by 200 µg/
ml hrDMBT1 in Curosurf®, it required more than 3 mM
CaCl2 to obtain a comparable effect for bovine Alveofact®.
Bernhard et al. showed improved function of Alveofact®
and Curosurf® when increasing calcium to nonphysiologic
concentrations of 3 mM and 4 mM, respectively [33]. Cal-
cium has previously been shown to improve spreading
and adsorption of surfactant [34]. This effect of calcium
can probably be explained by increased aggregation of
surfactant lipids, thereby forming larger and more effec-
tive aggregates [33,35-37]. A beneficial effect of calcium
on the surface tension of Curosurf® has also been found in
incubation experiments with meconium [34]. Surfactant
inactivation by meconium was also associated with
altered surfactant morphology [38,39] which could be
improved by increased calcium concentrations [34].
Several differences between the two surfactants may con-
tribute to the increased resistance of Curosurf® to
hrDMBT1 when compared with Alveofact®. Curosurf® con-
tains higher amounts of phosphatidylinositol, phosphati-
dylethanolamine, sphingomyelin and
phosphatidylserine, and higher concentrations of polyun-
saturated fatty acid-containing phospholipids and of plas-
malogens than Alveofact® [7]. In vitro Curosurf® is a
stronger inhibitor of induced neutrophil activation than
Alveofact® [40]. Meconium induced a significant increase
in minimum surface tension at a concentration of ≥0.02
mg/ml for Alveofact® and at ≥0.04 mg/ml for Curosurf®
[41].
Decreased surface activity of surfactant indicates impaired
ability of surfactant to keep the terminal conducting air-
ways and alveoli open. Up-regulated concentrations of
DMBT1 may contribute to oxygenation difficulties by
either interfering with the function of the endogenous sur-
factant and/or leading to a decreased efficacy of exoge-
nously added surfactant preparations, such as Curosurf®
and Alveofact®. This raises the possibility that DMBT1, in
addition to its role in innate host defense, may function
by influencing the surface tension of pulmonary sur-
factant.
Conclusion
Our results demonstrate that preterm and full-term
infants express DMBT1 in the lung. Respiratory DMBT1
may modulate surface activity of exogenous surfactant in
an unfavorable manner, thereby possibly contributing to
oxygenation defects. Thus, inhibitors of these DMBT1-
mediated effects could represent useful agents to counter-
act neonatal lung disease, intractable surfactant deficiency
and respiratory failure in addition to drugs already used in
neonatal intensive care units such as prenatal corticoster-
oids and surfactant. To confirm such relationships follow-
up studies are required that address potential correlations
between increased DMBT1 levels in bronchoalveolar fluid
and inactivation of exogenously added surfactant prepara-
tions in vivo.Page 8 of 10
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